Denali Therapeutics Inc. ( DNLI) - Key Metrics
DNLI Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.02 | -$0.68 | -$0.52 | -$0.52 |
| 2026Q1 | $0 | -$0.69 | -$0.70 | -$0.72 |
| 2025Q4 | $0 | -$0.73 | -$0.56 | -$0.57 |
| 2025Q3 | $0 | -$0.74 | -$0.62 | -$0.61 |
| 2025Q2 | $0 | -$0.72 | -$0.44 | -$0.46 |
DNLI Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -9.46 |
| 2026Q1 | 0% | -6.96 |
| 2025Q4 | 0% | -5.65 |
| 2025Q3 | 0% | -4.91 |
| 2025Q2 | 0% | -4.86 |
DNLI
Price: $24.40
52 week price:
Earnings Per Share: -2.84 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 517900
Market Capitalization: 4.0 billion